Clinical trial
Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory…
NCT00004032 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004032 |
|---|---|
| Title | Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer |
| Official title | Intraperitoneal (IP) Autologous Therapeutic Tumor Vaccine AUT-OV-ALVAC-h.B7.1 Plus IP rIFN-gamma for Patients With Ovarian Cancer. A Pilot Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Ovarian Epithelial Cancer |
| Intervention type | Biological, Other |
| Interventions | ALVAC-hB7.1, recombinant interferon gamma, laboratory biomarker analysis |
| Enrollment | 12 |
| Start date | Oct 1, 1997 |
| Primary completion | Apr 1, 2004 |
| First posted | Aug 25, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: